Biotechnology News and Research

RSS

New research may open door to novel therapies for treating immune disorders

A new research discovery published in the April 2014 issue of the Journal of Leukocyte Biology may open the door to new therapies that help treat immune disorders or curb runaway inflammation. Specifically, scientists have discovered a molecule that can induce cell death (apoptosis) in a key type of immune cell (dendritic cells).

1 Apr 2014

NCCN ORP awarded grant to study effectiveness of enzalutamide in solid tumors

The National Comprehensive Cancer Network Oncology Research Program has been awarded a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of enzalutamide in solid tumors, including bladder, breast, endometrial, hepatocellular, ovarian, and prostate cancers.

1 Apr 2014

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Prana Biotechnology has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results.

31 Mar 2014

Verde Media Group, Biotech Division complete acquisition of Butazyme

Verde Media Group Inc. and its Biotech Division announce they have completed the acquisition of the privately held biotechnology company Butazyme LLC.

31 Mar 2014

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

31 Mar 2014

ICON agrees to acquire Aptiv Solutions for $143.5 million

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to certain closing conditions, to acquire Aptiv Solutions for a cash consideration of $143.5 million. Aptiv Solutions is owned by The Halifax Group, SV Life Sciences, Comvest Partners and Management.

31 Mar 2014

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).

31 Mar 2014

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to placebo in patients with high cholesterol.

31 Mar 2014

e-Therapeutics announces interim results from ETS2101 phase Ia trial for advanced solid tumours

e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.

31 Mar 2014

Dongkook Pharmaceutical to launch Probi Mage dietary supplement in South Korea

Probi has signed a distribution agreement with Dongkook Pharmaceutical Co., Ltd., based in Seoul, South Korea for the distribution of Probi´s gut health product, Probi Mage®. The Product will be launched under Probi's brand in South Korea in the second quarter of 2014.

31 Mar 2014

New gene-editing system holds potential for treating many genetic disorders

Using a new gene-editing system based on bacterial proteins, MIT researchers have cured mice of a rare liver disorder caused by a single genetic mutation.

31 Mar 2014

Study on effects of cholesterol-lowering medications on sexual health

A new study is giving hope to older men who are concerned about the effects of cholesterol-lowering medications on their sexual health.

31 Mar 2014

Integral Molecular announces new patent protecting use of lipoparticles for eliciting antibodies against protein targets

Integral Molecular, a leader in membrane protein antibody discovery, announces the issuance of a new patent protecting the use of Lipoparticles for eliciting antibodies against membrane protein targets.

29 Mar 2014

RXi Pharmaceuticals provides business update, reports Q4 and full year 2013 financial results

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.

29 Mar 2014

Nordion enters into definitive agreement to be acquired by Sterigenics

Nordion Inc., a leading provider of products and services to the global health science market, announced that it has entered into a definitive agreement (the "Arrangement Agreement") to be acquired by Sterigenics, a global leader in sterilization services and a portfolio company of GTCR LLC, a leading private equity firm based in Chicago, Illinois, USA.

29 Mar 2014

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Today Biogen Idec announced that the U.S. Food and Drug Administration has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body.

29 Mar 2014

Researchers develop potentially safer and more cost-effective therapeutics against West Nile virus

An international research group led by Arizona State University professor Qiang "Shawn" Chen has developed a new generation of potentially safer and more cost-effective therapeutics against West Nile virus and other pathogens.

29 Mar 2014

$Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM$

Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM

Patrys Limited, a clinical stage biotechnology company, is pleased to announce the final results from its Phase I/IIa, open-label study in patients with refractory or relapsed multiple myeloma (MM).

28 Mar 2014

BioTek to highlight latest microplate instrumentation technologies at Analytica 2014

BioTek Instruments, Inc., will highlight their latest microplate instrumentation technologies, designed to automate and improve lab efficiency, at Hall A3, Stand #310 during Analytica 2014, the 24th International Trade Fair for Laboratory Technology, Analysis and Biotechnology. The exhibition will be held April 1-4 at the Munich Trade Fair Centre / ICM in Munich, Germany.

28 Mar 2014

Cells measure surface area using cdr2p protein

One of the scientists who revealed how plants "do maths" can now reveal how cells take measurements of size. Size is important to cells as it determines when they divide.

28 Mar 2014

Biotechnology News and Research

New research may open door to novel therapies for treating immune disorders

NCCN ORP awarded grant to study effectiveness of enzalutamide in solid tumors

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Verde Media Group, Biotech Division complete acquisition of Butazyme

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

ICON agrees to acquire Aptiv Solutions for $143.5 million

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

e-Therapeutics announces interim results from ETS2101 phase Ia trial for advanced solid tumours

Dongkook Pharmaceutical to launch Probi Mage dietary supplement in South Korea

New gene-editing system holds potential for treating many genetic disorders

Study on effects of cholesterol-lowering medications on sexual health

Integral Molecular announces new patent protecting use of lipoparticles for eliciting antibodies against protein targets

RXi Pharmaceuticals provides business update, reports Q4 and full year 2013 financial results

Nordion enters into definitive agreement to be acquired by Sterigenics

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Researchers develop potentially safer and more cost-effective therapeutics against West Nile virus

Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM

BioTek to highlight latest microplate instrumentation technologies at Analytica 2014

Cells measure surface area using cdr2p protein

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News